AB Sciex and Leco support metabolomics
AB Sciex (Massachusetts, USA) and Leco (Michigan, USA) have formed a co-marketing partnership to provide support for researchers working in metabolomics in Europe and North America.
AB Sciex (Massachusetts, USA) and Leco (Michigan, USA) have formed a co-marketing partnership to provide support for researchers working in metabolomics in Europe and North America. Metabolomics researchers often use a systems biology approach that requires both liquid chromatography–mass spectrometry (LC–MS) and gas chromatography–mass spectrometry (GC–MS).
“We interact with metabolomics researchers all over the world, and we understand that there are times when metabolomics researchers want to use both GC–MS and LC–MS,” said Aaron Hudson, Senior Director, Academic and Omics Business, AB Sciex. Hudson added that the joint “bundles “ from AB Sciex and Leco provide users with improved felxibility in chromatography while obtaining the rich information that MS–MS delivers.”
Jeffrey Patrick. Director of Marketed Technologies at Leco, said his company’s GC–MS technologies complement the AB Sciex offerings and the combined portfolios offer expertise, services and support for metabolomics researchers.
The companies will offer “bundled” solutions for researchers requiring both separations. The application and service support teams from each company will work together.For more information please visit: www.leco.com or www.absciex.com
This story originally appeared in The Column. Click here to view that issue.
AOAC International Awarded NIST Grant for Developing Drug Testing Standards
October 31st 2024The grant will be part of a new collaborative scientific initiative to address the need for standards that define the desired performance of lateral flow immunoassay test strips to detect illicit drugs in tablets and powders.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
